NICE Doubtful On Cost-Effectiveness Of Tarceva
This article was originally published in The Pink Sheet Daily
The U.K.’s National Institute for Health and Clinical Excellence is asking for a further cost-effectiveness analysis of Roche’s Tarceva to weigh against the cost effectiveness of AstraZeneca’s Iressa.
You may also be interested in...
NICE’s decision to severely restrict second-line use of Roche’s Tarceva and AstraZeneca’s Iressa will not help distance the drugs sufficiently from a chasing pack, including Boehringer’s Giotrif.
With rules in place about when to stop therapy, the U.K.'s National Institute for Health and Clinical Excellence clears Allergan's botulinum toxin, Botox for use as prophylaxis in patients with chronic migraine and who have tried other therapies.
The benefits of Roche's Tarceva as maintenance therapy for lung cancer are uncertain and the drug is not cost-effective, the U.K.'s cost regulator concludes in final guidance.